Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Hepatic Arterial Infusion Chemotherapy Combined With Iparomlimab/Tuvonralimab (QL1706) and Bevacizumab in Patients With Unresectable HER2-Negative Intrahepatic Cholangiocarcinoma:A Prospective Phase II Study

NCT07841574 is registered in ClinicalTrials.gov with Lianghe Lu as lead sponsor.

NCT NCT07841574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07841574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Hepatic Arterial Infusion Chemotherapy Combined With Iparomlimab/Tuvonralimab (QL1706) and Bevacizumab in Patients With Unresectable HER2-Negative Intrahepatic Cholangiocarcinoma:A Prospective Phase II Study
Lead sponsor
Lianghe Lu
Phase
Phase 2
Overall status
Recruiting
Start date
June 11, 2026
Completion date
June 30, 2029
Enrollment
35 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

intrahepatic cholangiocarcinoma